Human papillomaviruses (HPVs) are small, doublestranded DNA viruses that infect cutaneous and mucosal epithelial tissues in several ano-genital and skin regions and the tracheo-bronchial and oral mucosa. Ninety-nine percent of cervical cancers are positive for HPV DNA, and a subset of HPVs, known as high-risk (HR) types, including HPV16 and HPV18, is primarily associated with cancer development (57).
Human papillomaviruses (HPVs) are small, doublestranded DNA viruses that infect cutaneous and mucosal epithelial tissues in several ano-genital and skin regions and the tracheo-bronchial and oral mucosa. Ninety-nine percent of cervical cancers are positive for HPV DNA, and a subset of HPVs, known as high-risk (HR) types, including HPV16 and HPV18, is primarily associated with cancer development (57) .
A critical step in cervical neoplastic progression is the integration of HPV DNA into the host genome (33, 57) . Integration is associated with deletion of regions, including the El, E2, E4, and E5 open reading frames (ORFs), while E6 and E7 genes, together with the upstream regulatory region, are retained, and their deregulation, related to high-level expression throughout the epithelium, represents the main determinant of progression toward the malignant phenotype (47) .
The mechanisms that promote cervical neoplastic progression are not clearly understood. Recently, it has been reported that spontaneous loss of episomes in W12 cells, a unique model of progression of HPV16-related cervical neoplasia, is associated with increased expression of antiviral genes that are inducible by type I interferon (IFN) (37) . Accordingly, the treatment of W12 cells with IFN-␤ can dramatically accelerate the progression from an ostensibly episomal population to one in which only integrants remain (21) .
IFN-␤ is produced upon infection in many cell types and induces an antiviral state through paracrine IFN production and the subsequent activation of interferon-stimulated genes (ISGs) (49) . During viral infection, transcriptional induction of the IFN-␤ gene is mediated by induction and/or activation of transcription factors of the IFN regulatory factor (IRF) family, specifically, IRF-1, IRF-3, and IRF-7, which bind to a motif termed the interferon regulatory factor element (IRF-E), also known as the IFN-stimulated response element (ISRE), present in the promoter of ISGs (22, 54) .
IRF-1 was originally identified as a regulator of the virusinducible enhancer-like element of the human IFN-␤ gene (20) , but it was then recognized as being able to regulate several ISGs and amplify the IFN response (28) . IRF-1 is expressed at low levels in most cell types and is upregulated by different stimuli. Conversely, IRF-3 is constitutively expressed in the cytosol and, upon infection, is suddenly activated by phosphorylation that leads to its nuclear translocation and subsequent induction of target genes. IRF-7 is expressed at a low level in most cell types, where its expression can be induced by type I IFN. Similarly to IRF-3, IRF-7 is activated through phosphorylation, undergoes nuclear translocation, and is involved in the second wave of sustained IFN-␣/␤ production (22) .
IRF-1 and IRF-3 are well-known targets of HPV16 E6-and E7-mediated inhibition of host defense responses (4, 36, 42) . Less investigated is the role, in IFN system modulation, of the HPV16 E5 oncoprotein.
HPV16 E5 is a hydrophobic protein of 83 amino acids that associates with the Golgi apparatus, the endoplasmic reticulum, and nuclear membrane (17) . E5 exhibits transforming activity (52) and cooperates with E6 and E7 to induce a malignant phe-notype (6, 51, 56) . E5 is also able to modulate several cellular pathways through activation of the epidermal growth factor receptor (EGFR) in a ligand-dependent manner (11, 55) . It has been demonstrated that through EGFR, E5 can upregulate vascular endothelial growth factor (26) and can enhance cyclooxygenase 2 expression (27) . E5 also has a primary role in the productive phase of the viral life cycle (12, 18) and in the proliferative capacity of HPV-positive cells upon differentiation (40) . Before integration, when the HPV genome is episomal, the E5 mRNA is the most abundant viral transcript (50) ; however, it is no longer expressed by the integrated HPV DNA (47) , suggesting that unlike E6 and E7, which are clearly associated with the transformed phenotype, E5 might play an important role in the early phases of tumorigenesis. Since spontaneous loss of episomes and selection of integrants have been associated with an IFN signature (21, 37), we sought to investigate whether, among HPV early proteins expressed before viral integration, E5 was able to impact IFN signaling.
In this paper, we provide evidence that E5 functions as a positive regulator of IFN-␤ gene expression through the induction of IRF-1. We also demonstrate that E5-induced IRF-1 expression results in transcriptional activation of IRF-1-targeted ISGs.
These findings indicate that the HPV16 E5 protein, through stimulation of the type I IFN response, may contribute to the loss of viral episomes in infected cervical keratinocytes, accelerating the progression to invasive cancer. Moreover, our data identify HPV16 E5 and IRF-1 as potential therapeutic targets in HPV-associated premalignant lesions in order to limit selection of integrants.
MATERIALS AND METHODS
Cell lines and treatment. The spontaneously immortalized human keratinocyte cell line HaCaT has been stably transfected with the empty vector pMSG (HaCaT/pMSG) or HPV16 E5 gene (HaCaT/E5), under the control of the dexamethasone-inducible mouse mammary tumor virus (MMTV) promoter (35) , and these cells were a generous gift of A. Alonso (German Cancer Research Centre, University of Heidelberg, Heidelberg, Germany). Cells were grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, glutamine, and penicillin-streptomycin (Gibco, Karlsruhe, Germany) to 70 to 80% confluence. Cells were serum starved for 24 h and induced with 1 M dexamethasone for 24 h or different times, as indicated below. C33A cells (American Type Culture Collection, Manassas, VA) were grown in RPMI 1640 containing 10% fetal bovine serum, glutamine, and penicillin-streptomycin. The W12 cell line is derived from a cervical intraepithelial neoplasia (48) . The 20863 (W12E) and 20861 (W12G) subclones have been previously described (23) and were a generous gift of A. Venuti (Istituto Regina Elena, Rome, Italy).
Western blot analysis. Whole-cell extracts (50 g) were prepared as previously described (10) . Cytoplasmic and nuclear extracts (50 g) were obtained by using the NE-PER nuclear and cytoplasmic extraction kit (Thermo Fisher Scientific, Inc., Waltham, MA). Proteins were separated by 7.5% or 10% SDS-PAGE and transferred to a nitrocellulose membrane (Amersham Pharmacia Biotech, United Kingdom). Blots were incubated with anti-IRF-1 (1:200; sc-497; Santa Cruz Biotechnology Inc., Santa Cruz, CA), anti-IRF-3 (1:200; sc-9082; Santa Cruz Biotechnology), anti-phospho-IRF-3 (1:1,000; 4947; Cell Signaling Technology, Inc., Beverly, MA), anti-IRF-7 (1:200; sc-15994; Santa Cruz Biotechnology), anti-protein kinase R (PKR; 1:200; sc-707; Santa Cruz Biotechnology), anti-caspase 8 (1:200; 9746; Cell Signaling), anti-USF-2 (1:200; sc-862; Santa Cruz Biotechnolgoy), anti-␤-actin (1:200; sc-47778; Santa Cruz Biotechnology), and anti-rabbit-or anti-mouse-horseradish peroxidase-coupled secondary antibody (Amersham, Buckinghamshire, United Kingdom). Immune complexes were identified by using an enhanced chemiluminescence system (Amersham, Buckinghamshire, United Kingdom). The intensities of specific bands were measured by densitometry and are reported as the increase in relative expression in treated cells compared with control cells.
Real-time RT-PCR. Total RNA was isolated by the RNAzol B method (Biotecx Laboratories, Houston, TX), and it was reverse transcribed (2 g) using Moloney murine leukemia virus reverse transcriptase and oligo(dT) priming according to manufacturer's protocol (Retroscript Ambion, Austin, TX). Realtime reverse transcription-PCR (RT-PCR) was run in a LightCycler instrument (Roche Molecular Biochemicals, Indianapolis, IN) using the LightCycler FastStart DNA Master SYBR green I kit (Roche Diagnostics, Indianapolis, IN) with the following protocol: initial activation of HotStar Taq DNA polymerase at 95°C for 15 min, followed by 40 cycles of denaturation at 94°C for 15 s, primer-specific annealing for 15 to 30 s at different temperatures, and elongation at 72°C for 10 s. The following primers were designed for cDNA amplification: for E5, For (5Ј-CCACAACATTACTGGCGTGC-3Ј) and Rev (5Ј-GCAGAGGCTGCTGTTA TCCAC-3Ј); for IFN-␤, For (5Ј-GCAGCAGTTCCAGAAGGAG-3Ј) and Rev (5Ј-GCCAGGAGGTTCTCAACAAT-3Ј); for IRF-1, For (5Ј-AGCTCAGCTG TGCGAGTGTA-3Ј) and Rev (5Ј-CATGACTTCCTCTTGGCCTT-3Ј); for caspase 8, For (5Ј-AGAGCCTAGGAGAGCGATG-3Ј) and Rev (5Ј-CACCAT CAATCAGAAGGGAAG-3Ј); for PKR, For (5Ј-CGATACATGAGCCCAGA AAC-3Ј) and Rev (5Ј-GTTTCAAAAGCAGTGTCAC-3Ј). Primers for the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH), used as an internal control, were For (5Ј-CCAAAATCAAGTGGGGCGATG-3Ј) and Rev (5Ј-AAAGGTGGAGGAGTGGGTGTCG-3Ј). For each cDNA, we determined housekeeping gene and target gene sequences in triplicate. The comparative threshold cycle (C T ) method was used to determine the increase of transcript present in E5-expressing cells compared to controls (38) .
Transfection experiments and enzymatic assays. Transfection experiments were performed using the Lipofectamine transfection reagent (Invitrogen, Carlsbad, CA) according to the manufacturer's protocols. Cells were transfected with the following constructs: the construct encoding the IFN-␤ gene promoter/enhancer cloned upstream of the luciferase reporter gene (29) , the construct for p3500 (encoding the entire IRF-1 promoter from bp Ϫ34000 to ϩ168), the three portions of Gas/B (corresponding to the Ϫ199 to Ϫ89 region of the IRF-1 promoter), GAS (the Ϫ126 to Ϫ113 region of the IRF-1 promoter), and NK-B (the Ϫ89 to Ϫ16 region of the IRF-1 promoter), all cloned upstream of the luciferase reporter gene (39) ; the construct pISRE-TA-luc (Invitrogen, Carlsbad, CA), containing five copies of consensus IRF-E sequence upstream of the firefly luciferase gene; IRF-1-expressing vector (29) ; E5 expression vector (3). Cells were transfected with 500 ng of luciferase reporter constructs and 500 ng of expression vectors. The amount of transfected DNA was adjusted with the empty vector RcCMV. One hundred nanograms of pAct-Renilla plasmid was cotransfected and used as a control for transfection efficiency. Reagents from Promega were used to assay extracts for luciferase activity in a Lumat LB9501 luminometer (E&G Berthold, Bad Wildbad, Germany).
ChIP assays. Chromatin immunoprecipitation (ChIP) assays were performed as previously described (13, 41) . Briefly, HaCaT/E5 and HaCaT/pMSG cells treated for 24 h with dexamethasone and W12E/G cells were cross-linked with 1% formaldehyde and quenched in 0.125 M glycine. The cell lysates were sonicated and immunoprecipitated with normal rabbit serum (BD) or anti-IRF-1-specific antibodies (Abs; Santa Cruz Biotechnology). The immunoprecipitated DNA was eluted and amplified by real-time PCR by using an ABI 7700 system (Applied Biosystems). Values were normalized to the corresponding input control and are expressed as the relative level of binding to normal rabbit serum for each experiment. The sequences of specific primers used for amplification of the human IFN-␤ (hIFN-␤) gene were as follows: For, 5Ј-GTCATTCACTGAAAC TTTA-3Ј; Rev, 5Ј-AGGTTGCAGTTAGAATGTC-3Ј. Real-time PCR was performed as previously described (13) .
Knockdown of IRF-1 expression. IRF-1 small interfering RNA (siRNA) oligonucleotide target sequences were selected and inserted in retroviral vectors as described previously (46) . The ability of the DNA construct to silence IRF-1 expression was assessed by Western blotting using 50 g of whole-cell extracts from HaCaT/E5 cells harvested 48 h after transfection with IRF-1 siRNA or luciferase siRNA and treated for 24 h with dexamethasone.
Neutralizing assay. HaCaT/pMSG and HaCaT/E5 cells were treated or untreated with 1 M dexamethasone and 500 IU/ml of IFN-␤1a (Rebif; Serono, Geneva, Switzerland) for 24 h in the presence or absence of 1,000 IU/ml sheep antiserum raised against human IFN-␣ and IFN-␤ (PBL Biomedical Laboratories, New Brunswick, NJ). The E5-mediated expression of IRF-1 was assessed by Western blotting as described above.
Enzyme-linked immunosorbent assay. To measure cell-associated IFN-␤, cells were lysed in buffer containing 50 mM HEPES (pH 7.6), 150 mM NaCl, 1% Triton X-100, 1 mM Na 3 VO 4 , 10 mM NaF, 30 mM Na 4 P 2 O 7 , 10% glycerol, 1 mM benzamidine, 1 mM dithiothreitol, 10 g/ml leupeptin, 1 mM phenylmethylsulfonyl fluoride. One hundred micrograms of total protein extract was then analyzed to determine the level of IFN-␤ by using a sensitive enzyme-linked immunosorbent 
RESULTS
The HPV16 E5 protein induces IFN-␤ expression. HPV16 E5 expression in dexamethasone-treated HaCaT/E5 cells was assessed by real-time RT-PCR of E5 transcripts, since no antibodies to the protein are available. E5 transcripts were not detected in dexamethasone-treated HaCaT/pMSG control cells, whereas enhanced levels of E5 transcripts were present in dexamethasonetreated HaCaT/E5 cells. E5 expression also appeared in dexamethasone-untreated HaCaT/E5 cells, indicating that, as reported elsewhere (35) , in the absence of the inducer the MMTV promoter was not completely shut off (Fig. 1A) .
We investigated IFN-␤ expression in HaCaT/E5 cells compared with HaCaT/pMSG control cells. As shown in (Fig. 1A, lane 2) .
We next correlated the kinetics of E5 expression with IFN-␤ gene induction. RNA was isolated from HaCaT/E5 cells treated with dexamethasone for 6, 12, or 24 h and then analyzed by real-time RT-PCR. Along with enhanced expression of E5 mRNA for up to 24 h ( Fig. 1D; 3 .5-fold increase), IFN-␤ mRNA basal expression was increased during the treatment time ( Fig. 1E; 6 .5-fold increase).
To confirm these findings in another system not dependent on dexamethasone, we transiently transfected an E5 expression vector in C33A human keratinocytes and assessed endogenous IFN-␤ expression and IFN-␤ gene promoter activity in comparison to cells transfected with the empty vector. As shown in Fig.  2A , dose-response experiments indicated a specific E5-mediated increase in IFN-␤ mRNA accumulation of up to 6-fold. Similarly, a substantial enhancement in IFN-␤ promoter activity was observed with increasing doses of E5-expressing vector compared with cells transfected with the empty vector (Fig. 2B) .
To study IFN-␤ gene induction by the HPV16 E5 protein in a more natural setting, we performed experiments in the HPV16-positive cervical epithelial cell line W12, a unique model of cervical squamous carcinogenesis. In particular, two selected clones of W12 were used: W12E, in which several copies of the genome are maintained episomally (clone 20863, a bona fide model for the productive infection), and W12G, which contains only integrated genomes (clone 20861, a bona fide model for virus-transformed cells) (23) . E5 expression in these cells was assessed by real-time RT-PCR and, as shown in Fig. 2C , only W12E cells expressed E5 at high levels (ϳ30-fold) compared with dexamethasone-induced HaCaT/E5 cells. Conversely, no detectable levels of E5 were present in W12G cells. Consistently, a substantial stimulation of IFN-␤ mRNA accumulation was observed only in W12E cells, while it was repressed in W12G cells (Fig. 2D) .
We also measured IFN-␤ protein production in HaCaT and W12 cells. Since secreted IFN-␤ protein was not detected by ELISA in conditioned medium of HaCaT or W12 cells, as already observed with transforming growth factor ␤ (34), we measured intracellular production of IFN-␤ in cell lysates by ELISA (Fig. 2E) . Consistent with the results obtained at the mRNA level, production of IFN-␤ was substantially and reproducibly increased in both dexamethasone-treated HaCaT/E5 and W12E cells.
Together, these results indicate that, in human keratinocytes, HPV16 E5 expression correlates with an increased IFN-␤ expression mediated by enhanced transcriptional activity.
The HPV16 E5 protein does not modulate IFN-␤ master regulator activity. To shed light on mechanisms leading to E5-mediated IFN-␤ induction, we investigated expression and activity of IFN master regulators, i.e., IRF-3 and IRF-7, in HaCaT cells treated with dexamethasone for 24 h. Western blot analysis indicated that E5 did not affect basal IRF-3 expression (Fig. 3A) . We then examined activation of IRF-3 by blotting with specific antibodies that recognize the phosphorylated protein form. As shown in Fig. 3B , no phosphorylated IRF-3 was detected in E5-expressing cells, which was instead observed in 293 cells transfected with IKK-ε, the IRF-3-activating kinase. A dexamethasone inhibitory effect on IRF-3 activation, which was recently reported (32), was excluded since the discrete amounts of E5 produced in the absence of the drug, while able to induce IFN-␤ expression (Fig. 1B and  C, lane 3) , did not activate IRF-3 (Fig. 3B, lane 4) . Similar to what was observed for IRF-3, IRF-7 activation, as assessed by detection of nuclear translocation of the protein, was not detected in E5-expressing cells (Fig. 3C) .
The HPV16 E5 protein induces IRF-1 expression. IRF-1 mRNA and protein expression levels in dexamethasonetreated HaCaT/E5 and W12E/G cells were evaluated by realtime RT-PCR and Western blot analysis, respectively. These analyses showed that IRF-1 levels were significantly increased in HaCaT/E5 cells compared with the HaCaT/pMSG control cells (Fig. 4A [2-fold increase] and B [4.2-fold increase]). Substantial induction of IRF-1 by E5 was also confirmed in W12 clones, in which high levels of IRF-1 expression were present only in E5-expressing W12E cells, compared with W12G cells (Fig. 4C and D) .
To determine whether the HPV16 E5 protein was able to induce IRF-1 promoter activity, HaCaT/E5 cells were transiently transfected with a 3,500-bp IRF-1 promoter construct cloned upstream of the luciferase reporter gene. Basal activity of the IRF-1 promoter showed a 2.5-fold increase (upper value) in E5-expressing cells compared to empty vector-expressing cells (Fig. 4E, lane 2 versus lane 1) . To assess which sequences on the IRF-1 promoter were involved in the observed effect, both cells were transfected with fragments of the IRF-1 promoter containing either consensus binding sites for STAT1 (GAS) or NF-B transcription factors, or a portion containing overlapping binding sites for STAT1 and NF-B (GAS/B). As shown in To assess whether this effect was also operative for IRF-1-specific target genes, the transcriptional activity of a synthetic reporter construct, pISRE-TA, bearing five copies of consen- HPV16 E5 stimulates ISG expression. To determine whether the regulation of IRF-1 by HPV16 E5 had an effect on host cell gene expression, we examined two IRF-1-targeted ISGs, PKR and caspase 8. Real-time RT-PCR data showed a significant increase of PKR and caspase 8 mRNA and protein accumulation in HaCaT cells expressing E5 compared with control cells (Fig. 8A and B and C and D, respectively). Induction of PKR and caspase 8 mRNA by E5 was also confirmed in W12 clones. As shown in Fig. 8E and F, substantially higher levels of PKR and caspase 8 were observed in E5-expressing W12E cells than in W12G cells.
DISCUSSION
There has been sustained interest in using IFNs and other immunomodulators to treat benign and premalignant HPVassociated lesions; however, inconsistent clinical outcomes have been observed (19, 24) , and the mechanistic bases for these inconsistencies are not yet understood.
In the present study, we addressed the role of the HPV16 E5 oncoprotein, which is expressed only before viral integration but is often lost as lesions progress toward malignancy, in type I IFN signaling. Our data demonstrate that E5, per se, is able to induce IFN-␤ by a mechanism involving IRF-1. An IFN gene expression signature is similarly induced by E5.
E5, together with E6 and E7, is considered an HPV oncoprotein (52) . The role of E6 and E7 in HPV-mediated cell transformation has been well established (15) , and both proteins have been implicated in IFN host response inhibition (4, 36, 42) . Similarly, the complete HPV31 genome has been shown to suppress some interferon-inducible genes in keratinocytes (8) . Conversely, the role of E5 in HPV-mediated carcinogenesis is still poorly understood, and its impact on the IFN system has not been yet defined. Interestingly, while E6 and E7 are expressed throughout the course of the disease and are required for transformed phenotype maintenance, E5 gene is often lost as lesions progress toward malignancy (47) . This suggests that E5 may play a critical role in the early phases of cell transformation before virus integration. Recently, in a proposed model of HPV16-induced cervical carcinoma, the loss of regulatory episomes appears to be a crucial step for selection of integrants and cancer progression. This event has been associated with a transient antiviral state inducible by type I IFN (21, 37) . Our results, showing that HPV16 E5 stimulates IFN-␤ and ISGs, make this protein a good candidate as the trigger to the transition phase from premalignant to malignant lesions when episomal viral forms are lost and expression of integrants is deregulated. Here we have also demonstrated that the increase in E5-mediated IFN-␤ expression is due to transcriptional activation. The induction of type I IFN is mainly regulated at the transcriptional level, wherein IRFs play central roles. Specifically, IRF-3 and IRF-7 have been implicated as main regulators of IFN gene transcription, with essential and distinct roles, and are responsible for prompt synthesis in response to infections. Indeed, IRF-3 is constitutively expressed in a variety of cell types, whereas IRF-7 is expressed at high levels only in plasmacytoid dendritic cells and is upregulated by IFN, lipopolysaccharide, and viral infection in most cell types. IRF-3 and IRF-7 are both activated by phosphorylation and then translocate into the nucleus, where they stimulate expression of target genes (22) . We found that the E5 protein did not activate either IRF-3 or IRF-7. Given the paucity of cell lines suitable for de novo HPV infection, it is difficult to study different aspects of virus replication and IFN stimulation. We therefore cannot rule out that in the setting of HPV natural infection, some viral replication intermediates may signal through cytosolic receptors, as recently demonstrated for Epstein-Barr virus (1), and induce IFN by activating IRF-3 and/or IRF-7.
Nevertheless, our data indicate that, in the absence of this At variance with IRF-3 and IRF-7, which are activated by phosphorylation, the different levels of IRF-1 expression are, indeed, one of the factors that dictate how it functions. Most cell types do not express IRF-1 at detectable levels, but its expression is rapidly induced at the transcriptional level following virus infection or exposure to various inducers, including IFNs and proinflammatory cytokines. We have shown that stimulation of IRF-1 expression by HPV16 E5 occurs through both the STAT1 and NF-B consensus sequences on the IRF-1 gene promoter. In agreement with these results, it has been reported that HPV16 E5 activates NF-B (27) . Conversely, so far no data on the modulation of STAT1 activity by HPV16 E5 have been reported. It will, therefore, be interesting to study the interference of this protein with signaling pathways triggered by IFN receptor engagement.
IRF-1 is a pleiotropic transcription factor that is critical for cell defense against viral infections but also crucial for the development of both the innate and adaptive immune responses (5, 30, 54) . High IRF-1 expression levels are required for the induction of a set of target genes, including ISGs (20, 28) . Notably, we have shown that E5 protein up-modulates IRF-1 expression at levels sufficient to stimulate ISG transcription. Indeed, in E5-expressing cells, IRF-1 upregulation in turn affects host gene expression mediated by IRF-E/ISRE. Among the E5/IRF-1-stimulated genes, we identified PKR and caspase 8, specific targets of IRF-1 (28, 43) . The role of PKR in the virus-induced antiviral response has been extensively demonstrated (16) ; however, recent reports also demonstrate that PKR is constitutively active in a variety of tumors and is required for tumor maintenance and growth (25) .
Caspase 8 belongs to a family of proteases and plays a key role in apoptosis (14) , but several nonapoptotic roles have been described, including promotion of cell motility, adhesion, and migration of cancer cells (31) . Interestingly, caspase 8, together with caspase 10, has been also reported as an essential component that mediates NF-B-dependent inflammatory responses in antiviral signaling (53) .
Interestingly, chronic inflammation has been identified as a cofactor for HPV-driven cervical carcinogenesis (7), and IRF-1 is induced by and is an effector of inflammatory cytokines. This raises the possibility that IRF-1, as already reported for E5-induced NF-〉 (27) , can mediate an inflammatory response during HPV infection. E5, through IRF-1 upregulation, can thus affect host gene expression on a more global setting.
Notably, we also demonstrated the functional relationship between E5 expression, IRF-1, and IFN signature stimulation in the unique model of HPV16-related cervical squamous carcinogenesis W12 cells (23) . This cell model has been extensively characterized, and it has been shown that it accurately resembles cervical neoplastic progression during long-term culture, with spontaneous transition from cells containing episomal HPV16 to a population containing only integrated HPV16 (2). It will therefore be interesting to assess whether the events that we have reported here are also seen in patients, based on analysis of IRF-1 expression and function during both active viral replication and selection of integrants. This could in part explain the various clinical outcomes of IFN therapy of papillomatoses and the differential regulation of HPV expression observed in various cancer cell lines upon IFN treatment (9, 19) . Similarly, studies on the effect of E5 protein on IFN expression in the natural context of the complete viral genome during a de novo HPV infection would help to further elucidate its normal functions, as already reported for E5 activity on cell proliferation (40) .
From our results, we can hypothesize the following scenario: during HPV productive episomal infection, stimulation of IRF-1 and IFN-␤ by E5 or other unchecked factors leads to the establishment of an antiviral state that, as reported, may accelerate episomal clearance (21, 37) . As soon as only integrated virus is transcriptionally active, E5 is no longer expressed, and the IFN-IRF-1-mediated response is shut down. Meanwhile, high expression levels of the E6 and E7 oncogenes lead to inhibition of expression and/or activity of IFN synthesis key factors and the IFN-induced signal transduction pathway.
Modulation of IRF-1 expression by viral proteins has been reported for different viruses and can result either in inhibition of its expression, as reported for HPV E7 (36) and HCV core protein (10), or in up-modulation, as we demonstrated in the setting of HIV-1 infection (41, 44, 45) and here for HPV16 E5. The final output of this modulation, however, can be always regarded as a bright way of hijacking a key immune regulator to turn its activity to the virus's advantage.
In conclusion, we have presented data defining a critical role of the HPV16 E5 protein in IFN-␤ expression stimulation mediated by increased IRF-1 protein accumulation in human keratinocytes. An IFN gene expression signature was similarly induced. Our findings highlight an important function for the HR-HPV E5 oncogene and once more underline that great care should be taken during interferon treatment of HR-HPVassociated cervical lesions.
Inhibition of E5 and/or IRF-1 expression may also represent a new avenue for therapeutic interventions in early phases of infection, when activation of the innate immune 
